TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04565353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study: NCT05297123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: All-trans retinoic acid (ATRA) 20mg 3 times a day for 8 weeks.
Study: NCT05297123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Realgar-Indigo naturalis formula
Description: 60 mg/kg/d for 8 weeks
Study: NCT02977156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexa-Vec
Description: IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
Study: NCT02655653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid administered
Description: Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid administered
Description: Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
Study: NCT00522184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-articular injection of etanercept

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular injection of steroid
Study: NCT04305912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: Subjects will be randomized to wear somofilcon A daily disposable lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: verofilcon A
Description: Subjects will be randomized to wear verofilcon A daily disposable lenses.
Study: NCT00950287

Intervention type: DEVICE
Intervention: No intervention
Description: The recordings will be performed in neonatal units with the preterm infant remaining in usual condition with limitations of external stimulation during the study period. The usual monitor will remain in function. The intervention of the nurses in case of apnea will not be modified during the study period. The recording will be obtained from derivation of the signal usually recorded by the monitor in use completed in one centre by a polysomnographic recording (Medtronics France SA), in order to test a possible influence of the sleep status on the detection.
Study: NCT04629885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin 400 IU vaginal gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo gel with identical appearance to the test product, used as reference treatment.
Study: NCT04714411

Intervention type: DRUG
Intervention: Omadacycline
Description: Omadacycline monotgherapy
Study: NCT02638090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: Administered per treatment arm guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Administered per treatment arm guidelines.
Study: NCT01573143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.
Study: NCT00913432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Description: 3 mg/kg/day oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Description: masitinib 6 mg/kg/day oral route
Study: NCT04029480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin 5 mg, oral, 1 tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin 5 mg, oral, 1 tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Description: Ertugliflozin 15 mg, oral, 1 tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ertugliflozin 15 mg
Description: Placebo to ertugliflozin 15 mg, oral, 1 tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ertugliflozin 15 mg
Description: Placebo to ertugliflozin 15 mg, oral, 1 tablet QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ertugliflozin 15 mg
Description: Placebo to ertugliflozin 15 mg, oral, 1 tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ertugliflozin 5 mg
Description: Placebo to ertugliflozin 5 mg, oral, 1 tablet QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ertugliflozin 5 mg
Description: Placebo to ertugliflozin 5 mg, oral, 1 tablet QD

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: The initiation and titration of insulin will be at the discretion of the investigator, based on local/regional/country guidelines.
Study: NCT02638090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Administered per treatment arm guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered per treatment arm guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered per treatment arm guidelines.
Study: NCT04029480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: The initiation and titration of insulin will be at the discretion of the investigator, based on local/regional/country guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive stable dose of background metformin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive stable dose of background metformin.
Study: NCT04568096

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized All-Trans Retinoic acid plus oral Tamoxifen
Description: After randomization and standard treatment The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study: NCT02638090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered per treatment arm guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered per treatment arm guidelines.
Study: NCT04317105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV
Study: NCT02656043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XPF-005
Description: Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03176745

Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout
Description: determination of lung clearance index using SF6 multiple breath washout

Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout
Description: determination of lung clearance index using SF6 multiple breath washout

Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout
Description: determination of lung clearance index using SF6 multiple breath washout

Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout
Description: determination of lung clearance index using SF6 multiple breath washout
Study: NCT04068597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Powder suspension for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Powder suspension for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral tablet
Study: NCT04438785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The intervention consists of myofunctional therapy (MT) using the AirwayGym app.
Description: Intervention. Patient newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the App AirwayGym 20 minutes a day during 90 days.
Study: NCT03635788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) Oral ART
Description: SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC) Oral ART
Description: SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral RPV
Description: RPV 25 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral RPV
Description: RPV 25 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CAB
Description: CAB 30 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral CAB
Description: CAB 30 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV-LA Loading Dose
Description: 900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPV-LA Loading Dose
Description: 900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB-LA Loading Dose
Description: 600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAB-LA Loading Dose
Description: 600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV-LA Maintenance Dose
Description: 600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
Study: NCT04317105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV
Study: NCT03635788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPV-LA Maintenance Dose
Description: 600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB-LA Maintenance Dose
Description: 400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
Study: NCT04317105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT02963727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton Jelly derived mesenchymal stem cell
Description: Intra-articular Wharton Jelly derived mesenchymal stem cell injection.
Study: NCT03919890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7684
Description: Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7684
Description: Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7684
Description: Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-7684 Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-7684 Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-7684 Placebo
Description: Placebo comparator
Study: NCT00619684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO
Study: NCT01173627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test fentanyl citrate 400 mcg troche
Description: Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actiq 400 mcg
Description: Actiq 400 mcg administered as a single dose under fasted conditions
Study: NCT03158649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embarazo y Bienestar
Description: The intervention programme is called Embarazo y Bienestar (Pregnancy and Well-being). Embarazo y Bienestar is a modular, self-placed program mainly designed to foster women's prenatal well-being by practicing some positive psychology-based exercises. The intervention programme consist of four modules of intervention, one welcome module, and a final resume page.
Study: NCT03679208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device coded KIO014
Description: Innovative chitosan-based biomaterial intended for intraarticular injection.
Study: NCT04317105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study: NCT03464552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: oral capsule 3 hours before procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposcopic guided biopsy
Description: Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.
Study: NCT04317105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03679208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device coded KIO014
Description: Innovative chitosan-based biomaterial intended for intraarticular injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durolane(r) as control device
Description: Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.
Study: NCT04120792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous exercise and cognitive training
Description: Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
Study: NCT04120792

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral video
Description: Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
Study: NCT02030561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab + NK cells
Study: NCT04317105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study: NCT04228172

Intervention type: GENETIC
Intervention: DNA/GeneticTesting
Description: Subjects will be tested for GBA and LRRK2 mutation status at baseline.

Intervention type: GENETIC
Intervention: DNA/GeneticTesting
Description: Subjects will be tested for GBA and LRRK2 mutation status at baseline.

Intervention type: RADIATION
Intervention: FDG PET scan
Description: 18F-Fluoro-2-deoxy-glucose (FDG) PET scan is a nuclear medicine test that measures glucose metabolism (energy) in your brain at baseline and 18 months later.

Intervention type: RADIATION
Intervention: FDG PET scan
Description: 18F-Fluoro-2-deoxy-glucose (FDG) PET scan is a nuclear medicine test that measures glucose metabolism (energy) in your brain at baseline and 18 months later.

Intervention type: OTHER
Intervention: MRI scan
Description: Magnetic Resonance Imaging (MRI) is a noninvasive scan which produces detailed pictures of the brain using a magnetic field. In addition, a special type of MRI, called resting state functional MRI (rs-fMRI), will measure and map brain activity. Conducted at baseline and 18 months later.
Study: NCT03635788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAB-LA Maintenance Dose
Description: 400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
Study: NCT02451293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin (N-acetyl-5-methoxytryptamine)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04035759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APPEAL
Description: Three-session, individually administered program, with sessions spaced monthly. Optional weekly contacts with participants to support engagement in program exercises/activities.
Study: NCT04228172

Intervention type: OTHER
Intervention: MRI scan
Description: Magnetic Resonance Imaging (MRI) is a noninvasive scan which produces detailed pictures of the brain using a magnetic field. In addition, a special type of MRI, called resting state functional MRI (rs-fMRI), will measure and map brain activity. Conducted at baseline and 18 months later.

Intervention type: OTHER
Intervention: Clinical and neuropsychological assessments
Description: Investigator will evaluate subjects according to the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the standard clinical tool used to measure the severity and progression of PD. Neuropsychological evaluation will assess how one's brain functions (via pencil and paper testing), which indirectly yields information about the structural and functional integrity of the brain. Conducted at baseline and 18 months later.
Study: NCT02069262

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rebleeding
Description: Those who developed rebleeding during the observation would be crossed over to the other investigation modality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rebleeding
Description: Those who developed rebleeding during the observation would be crossed over to the other investigation modality.